BioCryst Pharmaceuticals (BCRX) to Release Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is set to announce its earnings results before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period last year, the company earned ($0.28) EPS. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Trading Down 1.3 %

BCRX stock opened at $7.02 on Friday. The company has a market capitalization of $1.45 billion, a PE ratio of -6.56 and a beta of 1.88. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $7.93. The business’s fifty day moving average price is $6.69 and its 200 day moving average price is $5.77.

Analyst Ratings Changes

BCRX has been the topic of several recent research reports. JMP Securities upped their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $14.67.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Helen M. Thackray acquired 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average cost of $5.86 per share, with a total value of $175,800.00. Following the purchase, the insider now directly owns 272,139 shares of the company’s stock, valued at approximately $1,594,734.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Anthony Doyle acquired 36,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was purchased at an average cost of $5.57 per share, with a total value of $202,191.00. Following the purchase, the chief financial officer now directly owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Helen M. Thackray purchased 30,000 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $5.86 per share, with a total value of $175,800.00. Following the transaction, the insider now directly owns 272,139 shares of the company’s stock, valued at approximately $1,594,734.54. The disclosure for this purchase can be found here. Insiders bought 103,601 shares of company stock valued at $596,338 in the last ninety days. Corporate insiders own 4.80% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.